Induced Pluripotent Stem Cells (iPSC) Markers
Induced pluripotent stem cells (iPSCs) are a revolutionary development in stem cell culture, offering a unique avenue for regenerative medicine. These cells are created by reprogramming adult cells, typically skin or blood cells, to regain pluripotency—meaning they can differentiate into any cell type in the body. They not only eliminate the need for embryos but can be produced in a patient-specific manner, enabling each individual to have their own pluripotent stem cell line. This potential for an unlimited supply of autologous cells holds promise for generating transplants without the concern of immune rejection.
While the safety of iPSC technology for therapeutic transplants is still under evaluation, iPSCs are currently playing a crucial role in personalized drug discovery and enhancing our understanding of the individualized basis of diseases.
Phenotyping is the go-to technique to check and distinguish between different developmental stages in stem cell approaches. antibodies-online offers reliable marker for iPSC phenotyping in order to monitor the current state of your cells.
Induced Pluripotent Stem Cells (iPSCs) Cell Surface Antigenic Markers
- (1)
Undifferentiated Cell Markers
It is crucial to verify the continued pluripotency of your PSCs. A reliable method for assessing this is employing undifferentiated cell markers through techniques like western blot or ICC. The detection of key undifferentiated cell markers, including Oct4 and Sox2, serves as an initial and essential indicator of pluripotency in your cells.
- (11)
- (15)
- (1)
- (6)
- (14)
- (4)
- (8)
- (1)
- (8)
- (7)
Differentiation of Induced Pluripotent Stem Cells
Induced pluripotent stem cells (iPSCs) can differentiate into the three primary germ layers—ectoderm, mesoderm, and endoderm—mirroring the natural embryonic development process. To induce this differentiation, researchers employ specific signaling pathways and growth factors in the cell culture environment. This controlled differentiation process is crucial for the development of targeted therapies and the study of various diseases in a dish, providing a powerful tool for regenerative medicine and disease modeling. Antibodies-online offers reliable marker antibodies for the detection of the three primary germ layers.
Helpful Tips for iPSC Phenotyping
- Use Validated Markers: Employ well-established and validated markers for pluripotency and specific lineages to ensure accurate phenotyping.
- Use a combination of markers to enhance the accuracy of phenotyping.
- Check Pluripotency Regularly: Monitor key pluripotency markers (Oct4, Sox2, Nanog) routinely to confirm the maintenance of an undifferentiated state.
- Consider Functional Assays: Complement antibody-based phenotyping with functional assays, such as teratoma formation or embryoid body differentiation, to confirm pluripotency.
- Use Time Points: Assess iPSCs at different time points during differentiation to capture the progression through various developmental stages.
- Evaluate Genomic Stability: Check for genomic stability using karyotyping or other genomic assays to ensure the maintenance of chromosomal integrity.
- Ensuring proper culture conditions and check for mycoplasma contamination.
- Ensure Reproducibility: Validate phenotyping protocols across different experiments and laboratories for robust results.
References
- : "Evaluation of commonly used ectoderm markers in iPSC trilineage differentiation." in: Stem cell research, Vol. 37, pp. 101434, (2020) (PubMed).
- : "Antibody screening using a human iPSC-based blood-brain barrier model identifies antibodies that accumulate in the CNS." in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 34, Issue 9, pp. 12549-12564, (2021) (PubMed).
- : "Robust detection of undifferentiated iPSC among differentiated cells." in: Scientific reports, Vol. 10, Issue 1, pp. 10293, (2020) (PubMed).
- : "Using intracellular markers to identify a novel set of surface markers for live cell purification from a heterogeneous hIPSC culture." in: Scientific reports, Vol. 8, Issue 1, pp. 804, (2018) (PubMed).
- : "Identification of marker genes to monitor residual iPSCs in iPSC-derived products." in: Cytotherapy, Vol. 25, Issue 1, pp. 59-67, (2022) (PubMed).
